We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 39

General Court of the EU Confirms Fines Imposed on Lundbeck and Generic Drug Manufacturers for Entering into Patent Settlements
  • McDermott Will & Emery
  • European Union
  • September 22 2016

On 8 September 2016, the General Court of the EU (GCEU) handed down five judgments upholding a decision by the Commission of 19 June 2013 imposing


Paying Royalties for Technology that Competitors Can Use for Free - AG Wathelet’s Genentech Opinion
  • McDermott Will & Emery
  • European Union
  • April 28 2016

The Court of Justice of the European Union (CJEU) recently issued its opinion on a question referred to it by the Paris Court of Appeal regarding the


European Commission fines pharmaceutical companies for Citalopram pay-for-delay agreements
  • McDermott Will & Emery
  • European Union
  • June 30 2013

On 19 June 2013, the European Commission announced a fine of 93.8 million for H. Lundbeck AS (Lundbeck) and a further 52.2 million of fines levied


UK Supreme Court steps into line with Europe, but rejects U.S. approach
  • McDermott Will & Emery
  • United Kingdom, USA, European Union
  • November 30 2011

The UK’s highest court recently considered the provisions of the European Patent Convention (EPC) centering on the “susceptible of industrial application” requirement in the context of a patent describing a DNA sequence for a new protein, Neutrokine-α, which was a member of a group of similar proteins known as the TNF ligand superfamily


SPCs: is a simplistic system becoming too complicated?
  • McDermott Will & Emery
  • European Union
  • November 22 2010

Obtaining and enforcing Supplementary Protection Certificates (SPCs) for medicinal products in the European Union is a fertile ground for challenge and the law is still unclear in a number of key areas


Advocate General opinion on the interpretation of “first marketing authorisation” for Supplementary Protection Certificates
  • McDermott Will & Emery
  • European Union
  • June 7 2012

Advocate General Trstenjak (the AG) has rendered an opinion in a preliminary reference relating to Neurim Pharmaceuticals Ltd 1991 C-13011 that it should be possible to grant a Supplementary Protection Certificate (SPC) for a second medicinal product that comprises the same active ingredient as a medicinal product covered by a prior marketing authorisation (MA), if the scope of the basic patent protecting the second medicinal product does not extend to the earlier medicinal product


Navigating the evolving regulation and commercialization of stem cell research
  • McDermott Will & Emery
  • European Union, USA
  • March 22 2012

Interested parties that can successfully navigate the evolving regulation of stem cell research stand to gain significant scientific and commercial advantage



Paul Devinsky
  • McDermott Will & Emery

Jacques Buhart
  • McDermott Will & Emery